HIV protease inhibitor substitution in patients with lipodystrophy: a randomized, controlled, open-label, multicentre study

Medicine and Dentistry

• Human Immunodeficiency Virus 100%
• Human Immunodeficiency Virus Proteinase Inhibitor 100%
• Proteinase Inhibitor 100%
• RNA 66%
• Abacavir 66%
• Antiretroviral Therapy 66%
• Lipodystrophy 66%
• Adefovir 66%
• Insulin Resistance 66%
• Cholesterol 33%
• Lipid 33%
• Triacylglycerol 33%
• Nevirapine 33%
• Lipid Storage 33%
• Drug Withdrawal 33%
• Glycemic 33%
• Abdominal Fat 33%
• Nucleoside Analogue 33%
• Dyslipidemia 33%
• T Lymphocyte 33%
• High Density Lipoprotein Cholesterol 33%
• Hydroxyurea 33%
• Intra-Abdominal Fat 33%
• Lipoatrophy 33%
• Abdominal Subcutaneous Fat 33%
• Adverse Event 33%

Agricultural and Biological Sciences

• Protease 100%
• Abdominal Fat 50%
• Fat Body 33%
• RNA 33%
• Insulin Resistance 33%
• Adefovir 33%
• Abacavir 33%
• Endpoints 16%
• Lipids 16%
• Cholesterol 16%
• Triglyceride 16%
• High Density Lipoprotein Cholesterol 16%
• Dyslipidemia 16%
• Body Composition 16%
• Quality of Life 16%
• Nucleoside Analogue 16%
• Lymphocyte Count 16%
• Nevirapine 16%
• CD4 16%
• T Cell 16%